Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.

"Declarations FundingOpen Access funding enabled and organized by CAUL and its Member Institutions. This study was funded by an NHMRC Investigator Grant (APP1175929) held by Danny Rischin. Conflict of InterestAuthor Luke S. Mclean has received speaker honorarium and conference registration support from Sanofi and travel support/conference registration support from Merck, Sharpe & Dohme. Author Annette M. Lim provides uncompensated consultancy for Eisai and receives salary support from a Peter MacCallum Cancer Centre Discovery Partner Fellowship and institutional support from Sanofi/Regeneron Pharmaceuticals. Author Alesha A. Thai has received honorarium and is an advisory board member with BMS, Merck, La Roche Posay, and Akesobio. Author Danny Rischin is a member of trial steering committees and/or advisory boards (all uncompensated)—MSD, GSK, Regeneron, and Sanofi. He receives institutional trial funding from Merck Sharp & Dohme, Decibel Therapeutics, Bristol-Myers Squibb, GSK, Roche, Regeneron, Kura Oncology, and ALX Oncology. Author Mathias Bressel has no conflicts of interest that might be relevant to the contents of this article. Ethics Approval/Consent to Participate/Consent to PublicationThis retrospective study was approved by the Human Research Ethics Committee (HREC) (HREC/68865/PMCC) of the Peter MacCallum Cancer Centre, Melbourne, Australia, with a waiver for patient consent granted. Availability of Data and MaterialThe datasets generated during and/or analysed during the current study are not authorised to be publicly available under the current ethics approval. However, any queries regarding the datasets generated and analysed for this project may be directed to the corresponding author. Code AvailabilityAny queries regarding the code used for the analyses in this study may be directed to the corresponding author. Authors’ ContributionsAuthors LSM, AML, AAT, and DR contributed to the study concept and design. LSM and MB contributed to the data collection and analysis. The first draft of the manuscript was written by LSM. All authors commented on previous versions of the manuscript and read and approved the final version. Conflict of Interest Author Luke S. Mclean has received speaker honorarium and conference registration support from Sanofi and travel support/conference registration support from Merck, Sharpe & Dohme. Author Annette M. Lim provides uncompensated consultancy for Eisai and receives salary support from a Peter MacCallum Cancer Centre Discovery Partner Fellowship and institutional support from Sanofi/Regeneron Pharmaceuticals. Author Alesha A. Thai has received honorarium and is an advisory board member with BMS, Merck, La Roche Posay, and Akesobio. Author Danny Rischin is a member of trial steering committees and/or advisory boards (all uncompensated)—MSD, GSK, Regeneron, and Sanofi. He receives institutional trial funding from Merck Sharp & Dohme, Decibel Therapeutics, Bristol-Myers Squibb, GSK, Roche, Regeneron, Kura Oncology, and ALX Oncology. Author Mathias Bressel has no conflicts of interest that might be relevant to the contents of this article."

"Funding Open Access funding enabled and organized by CAUL and its Member Institutions. This study was funded by an NHMRC Investigator Grant (APP1175929) held by Danny Rischin."